Welcome to AiCuris: The Powerhouse for Anti-Infectives
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Topical Pritelivir: Phase 2 started
First subject enrolled in the clinical Phase 2 trial "LipP 1"
"LipP 1", the first clinical Phase 2 trial with topical Pritelivir for treatment of Labial Herpes has started.
NIH Support Preclin. Study AIC649
AiCuris Announces U.S. NIH Support of Preclinical Study with AIC649 against Chronic Hepatitis B
AiCuris, a leading company in the discovery and development of drugs against infectious diseases, today announced the start of a preclinical study on the proprietary immune modulator AIC649.
Letermovir: positive Phase 3 data
AiCuris’ anti HCMV drug Letermovir meets Primary Endpoint
AiCuris’ licensee Merck reports that Letermovir, a prophylactic treatment against HCMV in bone marrow transplant patients, meets Primary Endpoint in Pivotal Phase III Study.